NCT05334823 - A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

January 26, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

July 1, 2025

Conditions

Acute Lymphoblastic LeukemiaRelapsed Pediatric ALLRefractory Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

pCAR-19B cells

Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Trial Locations (10)

100000

RECRUITING

Beijing Children's Hospital.Capital Medical University, Beijing

RECRUITING

Beijing GoBroad Boren Hospital, Beijing

215000

RECRUITING

Children's Hospital Of Soochow University, Suzhou

300000

RECRUITING

Institute Of Hematology&Blood Diseases Hospital,Chinese Academy Of Medicai Sciences, Tianjin

330000

RECRUITING

The First Affiliated Hospital Of Nanchang University, Nanchang

410000

RECRUITING

The Second Xiangya Hospital, Central South University, Changsha

430000

RECRUITING

Pediatric Hematology department of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

RECRUITING

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

RECRUITING

Xiehe Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

610000

RECRUITING

West China Second University Hospital,Sichuan University, Chengdu

All Listed Sponsors

lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY